ENG

  • Cindy GUO

    Equity Partner / Shanghai

  • Tel +86-21-6061-3584

    Email guowen@zhonglun.com

  • Practices

    Investment/M&A & Corporate Governance, Private Equity & Investment Funds, Hong Kong & Overseas Capital Markets

CV

Cindy GUO

Cindy Guo specializes in cross-border M&A as well as investment and financing. She has long provided legal services to major multinational corporations in relation to their cross-border transactions. She has gained extensive experience in industries such as high-end manufacturing, biopharma, new materials, and new energy vehicles, and is particularly skilled in handling complex multi-jurisdictional M&A and restructuring transactions.

Since the beginning of her legal career, Cindy Guo has actively participated in major waves of foreign-related business, including foreign direct investment, cross-border M&A, and outbound investments of Chinese companies in the post-subprime crisis era. She has not only advised numerous Fortune 500 companies and multinational corporations on their investments in China but also represented large Chinese companies in multiple overseas investment projects. Through her extensive experience representing clients from compound roles and different jurisdictions, Cindy Guo has accurately developed deep insights and precise understanding into the commercial needs of clients. Cindy Guo excels at tailoring legal solutions that balance the interests of all parties, align with practical requirements and take into account the unique characteristics and regional attributes of different clients. Her professionalism and legal cultivation have earned her the lasting trust and recognition of her numerous clients.

In addition, Cindy Guo had been working as a seconded in-house counsel for 3M, where she was responsible for legal affairs related to their Chinese business in the healthcare and automotive industries.

Representative Matters

M&A and Corporate Restructuring

  • Advised Bausch Health's aesthetics business (a company listed on both NYSE and TSX), Solta Medical, on its successful acquisition of long-term distribution partner, Shibo Group

  • Advised the shareholders of Chengting Group, a renowned hearing aid retailer, on the sale of hearing aid retail business to Sonova, a Swiss listed company 

  • Advised SIIC Capital on its strategic investment in MicroPort Scientific Corporation, a Hong Kong listed company

  • Advised Huyue Fund of SIICFM on its investment in the restructuring project of Tsinghua Unigroup 

  • Advised ReLive, a tissue engineering and regenerative medicine company, on its acquisition of the German listed company co. don

  • Advised Mycronic AB, a Swedish listed company, on its acquisition of a controlling stake in Axxon, a leading company in SMT industry, establishment of a joint venture, and subsequent acquisition of the remaining equity

  • Advised Mycronic AB, a Swedish listed company, on its acquisition of a controlling stake in Huan Cheng Xin, a leading company in SMT industry, establishment of a joint venture, and subsequent acquisition of the remaining equity 

  • Advised Mycronic AB, a Swedish listed company, on its acquisition of atg Group from Cohu, a Nasdaq-listed company

  • Advised ALS, an Australian listed company, on the sale of its domestic geological inspection business to CTI, a Chinese A-share listed company

  • Advised ALS, an Australian listed company, on its sale of environmental inspection business in China to Suez Group, a French listed company

  • Advised ALS UK on its acquisition of equity interests in a Mongolian inspection company held by its JV partner

  • Advised Shanying Intl, a Chinese A-share listed company, on its acquisition of a Swedish company, Nordic Paper

  • Advised IPCO AB, a global leading steel strip industrial process solutions company, on its acquisition of Longwin New Material

  • Advised two funds of JAC Capital on their strategic investment in a Korea company, Bee Semiconductor Technology

  • Advised for a Danish multinational water treatment company in the bidding process on its acquisition of a major water treatment equipment company under PRC law, including but not limited to issuing legal due diligence report, etc.

  • Advised a famous German fan equipment manufacturer on its sale of the business in China from the perspective of PRC law

  • Advised a multinational pharmaceutical company on completing the sale of the overall rights and interests in Greater China of a drug for defect repairing of cartilage

  • Advised New Value Fund, a domestic investment fund, on its acquisition of a well-known education company, EIC Education, from CVC

  • Advised Fullshare Holdings, a Hong Kong listed company, on its acquisition of multiple real estate projects

  • Advised GLP, a leading logistics real estate company, on its acquisition of various logistics properties 

  • Advised Logos Property, a well-known Australian real estate fund, on its acquisition of logistics properties

  • Advised 3M, a US listed company, on its acquisition of a Chinese orthotics company


PE/VC and Other Investments

  • Advised AVATR, a high-end electric vehicle company, on its several-rounds financing

  • Advised Huming Fund of SIICFM on its investment in Unisoc 

  • Advised China Life Investment Management Co. on additional investments in its two real estates (Aldgate Tower & 10 Upper Bank Street) in London

  • Advised Goldman Sachs on its investment in Burger King

  • Advised a leading fabric technology company on its establishment, Series Angel and Series A financing

  • Advised a client on its investment in a renowned general artificial intelligence technology company

  • Advised a Chinese chip company, GEO-CHIP, on its Series B+ round financing

  • Advised OCBC on its investment in C+ round financing of a Suzhou autonomous driving company, CalmCar

  • Advised a biopharmaceutical company specializing in defect repairing of cartilage on its Series Angel financing

  • Advised ReLive Biotechnologies, a tissue engineering and regenerative medicine enterprise, on its multiple rounds of financing

  • Advised a Hong Kong listed company on its investment in a new energy vehicle company

  • Advised Wanxiang Auto, a high-tech company, on its financing project

  • Advised the founders' team of a game company, Gamepoch, on its financing project

  • Advised a 4C purification technology team from Stanford on its financing project 

  • Advised CDH on its investment in I-Mab, a leading innovative biotechnology company in China

  • Advised a renowned proteomics platform company on its financing project

  • Advised a Singapore fund on its investment in a Stanford medical device incubation team

  • Advised a medical group founders' team on its financing project

  • Advised a big data center on its financing project

  • Advised a US augmented reality technology company on its financing project

  • Advised a well-known fund on its investment in a Chinese futures company

  • Advised a Hong Kong listed company on its investment in a well-known domestic hotel group

Honors and Awards

For Individual

ALB China Client Choice, Asian Legal Business, 2025

Rising Stars 2022, China Business Law Journal, 2022

Next Generation Lawyers, Legal 500, 2017

Publications

Foreign Investment in Micro-Credit Companies in China, China Business Law Journal, April 2011

Related

  • Bar Admissions/Professional Qualifications

    PRC Bar, 2011

  • Education

    LL.M., University College London, 2008
    LL.B., Anhui University, 2007

  • Professional Experience

    Partner, non-equity partner, and associate, Zhong Lun Law Firm , 2014 - 2019
    Associate, Martin Hu & Partners, 2009 - 2014

  • Languages

    Chinese
    English